The Burlington, Mass.-based company said Sept. 14 that Cigna joins Centene, Highmark, Tricare, Health Care Service Corp., Palmetto GBA Medicare and BCBS companies in offering coverage for “deep transcranial magnetic stimulation.”
The BrainsWay product received De Novo FDA clearance in 2018 and fully launched on the market in 2019. Individuals 18 and older with OCD will be eligible for coverage if two or more medication trials and an evidence-based psychotherapy trial all fail and lead to no improvement in symptoms.
